WuXi Biologics, global contract research, development and manufacturing organization (CRDMO), will double capacity in its state-of-the-art drug substance facilities in Germany. 
 
WuXi has facilities in the United States, China, Singapore, Ireland, and Germany. In 2020 WuXi invested in the construction and adaptation of two facilities in Germany. The Chempark Leverkusen sterile filling and freeze-drying plant will add a second variable filling line. WuXi’s Wuppertal state-of-the-art drug substance facility will double total capacity. 
 
WuXi’s Leverkusen and Wuppertal facilities will further enhance the company’s commercial and clinical manufacturing capacities in Europe, strengthening global dual-sourcing network strategies. 
 
Managing director of WuXi Biologics Germany, Benjamin Minow, said, “WuXi Biologics’ increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company’s global strategy to work in close proximity to our clients. Germany is a leading biotech and pharma hub. The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics’ long-term growth strategy.”